JAK3 and rheumatoid arthritis: In addition, the recent development of drugs inhibiting the TYK2-related proteins JAK1, JAK2 and JAK3 for the treatment of RA (including the drug tofacitinib, recently approved by the food and drug administration [FDA]), further support TYK2 as an appealing candidate drug target [54,64].